Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

eIF4E inhibitor

- PMLiVE

BMS and Pfizer to donate $1m for cardiovascular education

The money will be distributed between seven organisations

- PMLiVE

Pfizer acquires option to license potential Parkinson’s treatment

Medgenesis cuts exclusive deal for its GDNF treatment

- PMLiVE

Rapid review for Pfizer’s superbug vaccine

FDA to expedite assessment of Clostridium difficile inoculation

- PMLiVE

Pfizer and Merck expand anti-PD1 cancer alliance

Will investigate combination of pembrolizumab and Xalkori

- PMLiVE

ViiV bags US approval for HIV blockbuster-in-waiting

Drug combines antiretrovirals with Tivicay

- PMLiVE

US panel backs pneumococcal vaccines for seniors

Vaccines to be provided by Merck & Co and Pfizer

- PMLiVE

Pfizer to work with genetics firm on bowel disease

Agrees deal with 23andMe to research ulcerative colitis and Crohn’s disease

- PMLiVE

Pfizer closes on $1bn label expansion for Prevenar

EMA begins review of the pneumococcal vaccine

- PMLiVE

Pfizer’s arthritis drug Enbrel widens its European licence

Gains new indication for early-stage inflammatory joint disease

- PMLiVE

Pfizer acquires Baxter Men C and encephalitis vaccines for $635m

Snaps up marketed vaccines and part of Baxter's Austrian manufacturing plant

- PMLiVE

European licence for BMS/Pfizer’s Eliquis in DVT and PE

Anticoagulant catches up with Bayer's Xarelto and Boehringer's Pradaxa

- PMLiVE

Pfizer inks $360m deal to buy InnoPharma

Boosts position in the buoyant sterile injectables market

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links